Galena Biopharma

NASDAQ

- -

- -

- -

- -

- -

- -

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs. The company’s lead product candidate, NeuVax (nelipepimut-S), is in Phase III clinical trials for the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human epidermal growth factor receptor (HER2) expression; Phase IIb clinical trials in combination with Herceptin for HER2 1+/2+ node-positive and high-risk node-negative breast cancer treatment; and Phase II clinical trials in combination with trastuzumab for node positive and negative HER2 IHC 3+ patients. It also develops GALE-301 (folate binding protein), which is in Phase IIa clinical trials for the prevention of recurrence in patients with ovarian and endometrial cancers; GALE-302, a version of the E39 peptide that is in Phase 1b clinical trial for investigating a novel vaccination series; and GALE-401 (anagrelide controlled release), which is in a Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. Galena Biopharma, Inc. has strategic development and commercialization partnership with Dr. Reddy's Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.